Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...
Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.
Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.
A man living with advanced liver cancer has seen his tumour shrink by over half as “exciting” new clinical trials are ...
A groundbreaking cancer study led by Professor Tom Bird from the Cancer Research UK Scotland Institute has discovered a drug ...
Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, ...
Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...
Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...
CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback